QIAGEN N.V. (NYSE: QGEN) announced plans to expand its QIAcuity digital PCR ecosystem with new gene expression capabilities and workflow automation features, according to a company statement.

The Netherlands-based molecular diagnostics company plans to launch QIAcuity Gene Expression Assays in 2026 for human, mouse and rat research applications. The company also intends to introduce the QIAcuity OneStep High Multiplex Probe PCR Kit, which will enable analysis of up to 12 RNA targets in a single reaction.

QIAGEN is expanding its cell and gene therapy quality control portfolio to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio includes the QIAcuity HEK293 resDNA Sizing Kit for measuring host-cell DNA concentration and fragment size distribution.

The company plans to release QIAcuity Software 3.5 later this month, which will include analysis templates and automated reporting capabilities. The software will allow users to define analysis and reporting parameters before beginning a run.

QIAGEN has collaborated with Hamilton to automate QIAcuity digital PCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing.

The company reported over 3,200 cumulative QIAcuity placements worldwide since the platform's launch. More than 400 customers operate multiple QIAcuity instruments, and over 1,100 scientific publications reference the platform.

"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN.

QIAGEN will discuss its QIAcuity strategy during a webcast event scheduled for June 15, 2026.